

Cardiovascular and Interventional Radiological Society of Europe



GEST 2015



E U R O P E

**Global Embolization
Symposium and Technologies**

POCKET GUIDE

**June 24-27
Seville | Spain**

www.gest2015.eu



CIRSE foundation

2	2 Important Addresses 3 Committees 4 General Information 8 Hands-on Workshops	
12	Wednesday – Scientific Programme	WED
19	Thursday – Scientific Programme	THU
26	Friday – Scientific Programme	FRI
33	Saturday – Scientific Programme	SAT
37	Sponsored Activities 37 Satellite Symposia 53 Learning Centres 57 Sponsors Hands-on Workshops	
58	Exhibitors and Sponsors 58 Technical Exhibition, Alphabetical List 59 Technical Exhibition, Numerical List 60 Technical Exhibitors Guide	

Important Addresses

Congress Venue

Fibes II – New Conference Centre

Avda. Alcalde Luis Uruñuela
41020 Seville
Spain

Organising Secretariat

CIRSE Central Office

Neutorgasse 9
1010 Vienna
Austria

Phone: +43 1 904 2003

Fax: +43 1 904 2003 30

E-mail: office@esir.org

www.gest2015.eu

Committees

Advisory Board

Anna-Maria Belli (UK)

Jafar Golzarian (US)

Ziv J. Haskal (US)

Michael J. Lee (IE)

Marc R. Sapoval (FR)

Scientific Programme Committee

Christoph A. Binkert (CH)

Jafar Golzarian (US)

Patrick Haage (DE)

Ziv J. Haskal (US)

Michael J. Lee (IE)

Robert J. Lewandowski (US)

Robert A. Morgan (UK)

Charles E. Ray, Jr. (US)

Marc R. Sapoval (FR)

General Information from A to Z

Badges

Your personalised badge is your admission card to the congress. For organisational and security reasons, badges have to be worn at the congress venue at all times. A lanyard will be given to you with the congress bag. Identity checks in the congress centre may occur at any time. In case of loss, a replacement badge will be provided for an administrative charge of €80.

Certificate of Attendance

To obtain your certificate of attendance, you can choose one of the following options:

Print your certificate onsite at the congress

Starting Friday, June 26, 10:00, you can use one of the dedicated workstations in the registration area to print your certificate. All you need is your congress badge.

Print your certificate at home

After the congress you will be able to print your certificate of attendance at www.gest2015.eu. All you will have to do is provide your badge number. Alternatively, you could log into your personal CIRSE account at www.cirse.org with your personal log-in details.

CME Credit Allowance

The CIRSE Foundation is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The GEST Europe 2015 is designated for up to 21 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

General Information

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

Coffee Breaks, Snacks & Meals

The coffee break corners are located within the exhibition area.

Wednesday, June 24	09:45–10:15	15:45–16:15
Thursday, June 25	09:45–10:15	15:45–16:15
Friday, June 26	09:45–10:15	15:45–16:15
Saturday, June 27	09:45–10:15	

Disclaimer

CIRSE cannot accept any liability for the acts of the suppliers to this meeting or the attendees' safety while travelling to or from the congress. All participants are strongly advised to carry adequate travel and health insurance, as CIRSE cannot accept liability for accidents or injuries that may occur.

Disclosures

For financial disclosures and conflict of interest statements of the GEST Europe 2015 Faculty, please refer to www.gest2015.eu.

ESIRonline – www.esir.org

ESIRonline is the largest online presentation database for interventional radiology, featuring slides and webcasts from CIRSE meetings since 2006. With a large section covering embolisation topics, ESIRonline is the ideal tool for your research and educational needs. Presentations recorded at GEST Europe 2015 will be integrated shortly after the meeting. Access to all content is free for CIRSE members and congress attendees: visit www.esir.org and log in using your CIRSE membership or congress registration log-in details to start browsing!

Evaluation

To complete the session evaluation and obtain credits for your attendance at GEST Europe 2015 sessions please use the online evaluation system, accessible through the mobile app (icon on the GEST Europe 2015 home screen) and at <https://eval.webges.com/gest2015>.

**Internet**

A free wireless service is available to all delegates throughout the congress centre.

Network: GESTEUROPE2015

Password: gesteuropa2015

Mobile App

Get the GEST Europe 2015 event in the CIRSE mobile app to plan your personal congress programme, evaluate sessions, browse the exhibition and submit questions to the moderator in selected sessions. Available for iPhone, iPad and Android.

Mobile Phones

Please do not forget to turn your mobile phone to silent mode during the sessions.

Recording and Photographs

Please note that any form of recording, filming or photographing of presentation material during the sessions is strictly forbidden. Subject to the authors' consent, all presentation material will be made available online on CIRSE's educational platform ESIOnline.

Registration Desk – Opening Hours

Tuesday, June 23	16:00–18:00
Wednesday, June 24	07:00–18:00
Thursday, June 25	06:30–18:00
Friday, June 26	07:30–18:00
Saturday, June 27	07:30–11:00

Smoking

GEST Europe is a non-smoking congress. Smoking is permitted outside the congress centre only.

Speaker Centre

The Speaker Centre is located on the first floor of the congress centre. Please note that only digital material will be allowed for oral presentations. All material must be in English and provided on a CD-ROM, DVD-ROM or USB flash drive (which is preferred) to be placed on the central server onsite. All presentation files must be uploaded at least 3 hours prior to the beginning of the corresponding session.

Computers connected to the local server allowing access to the speakers' presentations are available in every lecture room. These computers are equipped with Microsoft Windows 7 Professional and Microsoft Office 2010 Professional. Please note that speakers are not allowed to use their own laptops for their presentations.

Opening Hours

Tuesday, June 23	16:00–19:00
Wednesday, June 24	07:00–18:00
Thursday, June 25	07:00–18:00
Friday, June 26	07:30–18:00
Saturday, June 27	07:30–11:30

Sponsors and Exhibitors

Please find a floor plan of the exhibition on the inside of the front cover and a detailed list of all exhibitors and sponsors on pages 58-59.

Opening Hours

Wednesday, June 24	09:30–17:30
Thursday, June 25	09:30–17:30
Friday, June 26	09:30–17:30
Saturday, June 27	09:30–12:00

Tourist Information and Hospitality Desk

For information regarding restaurants and excursions please visit the desk of our official travel partner, Kuoni, located at the registration area. Kuoni will be pleased to help you with all matters related to your stay in Seville.

Hands-on Workshops

Coils & Plugs

*Coordinators: K.A. Hausegger (Klagenfurt/AT),
O. van Delden (Amsterdam/NL)*

*Instructors: A. Basile (Catania/IT), E. Brountzos (Athens/GR),
M. Darcy (St. Louis, MO/US), A. Fohlen (Caen/FR),
G.A. Maleux (Leuven/BE), O. Pellerin (Paris/FR),
J. Urbano (Madrid/ES), P. Vilares Morgado (Porto/PT)*

This workshop gives participants the opportunity to work with a variety of coils, plugs and delivery devices using flow models. Operators of all experience levels are welcome. Experienced instructors will supervise participants as they explore using the material, and will share their best technical "tips and tricks".

Learning Objectives:

- To become familiar with different types of coils and plugs and their specific properties
- To become familiar with different kinds of delivery devices for coils and plugs and their specific properties
- To learn about the various techniques used to deploy coils and plugs
- To become aware of the kinds of problems that can be encountered during coil and plug placement, and how to potentially solve them

Wednesday, June 24

HoW 1 14:15–15:45

Wednesday, June 24

HoW 2 16:15–17:45

Thursday, June 25

HoW 3 14:15–15:45

Location: Hands-on Workshop Room (Paris)

Pre-registration was necessary. Should you not have pre-registered, please arrive at the workshop room well in advance to check availability.

Particles & Gelfoam

Coordinators: A. Fohlen (Caen/FR), H. Rio Tinto (Lisbon/PT), D. Vorwerk (Ingolstadt/DE)

Instructors: T.J. Kroencke (Augsburg/DE), K. Malagari (Athens/GR), K. Osuga (Suita, Osaka/JP), C.R. Weiss (Baltimore, MD/US)

This workshop will provide extensive information about, and hands-on exposure to, a large variety of particles and gelfoam. Both experienced practitioners and those at the beginning of their IR career are welcome. Supervised by the expert faculty, participants will have the opportunity to prepare the materials and discuss various aspects of their application, including particle size, preparation, indications, delivery and possible complications. This is a great opportunity for hands-on interaction with, and preparation of, both particles and gelfoam.

Learning Objectives:

- To become familiar with particulate agents and gelfoam, and to understand their specific features and applications
- To understand the proper embolisation technique and indications for the use of particles and gelfoam
- To understand the proper preparation and delivery of these embolic agents
- To become familiar with complications, both general and specific, that can result from the use of these agents, and how to minimise and manage them

Thursday, June 25

HoW 4

16:15–17:45

Location: Hands-on Workshop Room (Paris)

Pre-registration was necessary. Should you not have pre-registered, please arrive at the workshop room well in advance to check availability.

GET YOUR GEST EUROPE PROGRAMME VIA THE CIRSE SOCIETY APP!

Make the most of your visit to GEST Europe 2015

- Customise and share your programme
- Navigate the technical exhibition
- Submit questions to the moderators in selected sessions
- Use the online voting tool in the Morbidity and Mortality session
- No more paper forms: complete your session evaluation using the app



Glue, Onyx & liquid embolics, including sclerotherapy

Coordinators: J. Urbano (Madrid/ES), V. Vidal (Marseille/FR)

Instructors: H.T. Abada (Abu Dhabi/AE), M. Grosso (Cuneo/IT), M.J. Lee (Dublin/IE), R. Loffroy (Dijon/FR), O. Pellerin (Paris/FR), P. Rowlands (Liverpool/UK), S. Samuels (Miami, FL/US), W.F. Yakes (Englewood, CO/US)

The goal of this workshop is to provide a setting in which, under the direction of experienced faculty, participants become familiar with indications, management, advantages and risks of liquid and sclerosing agents. Liquid embolic agents are not particularly popular, but have certain properties that are very valuable and make them very powerful tools. Liquid agents may act as embolics, sclerosants or both. We welcome participants of all experience levels who are interested in gaining practical knowledge of the nuances of liquid embolic material choice, preparation, and delivery.

Learning Objectives:

- To know the indications of liquid embolic agents
- To understand the proper technique of glue and Onyx preparation and delivery
- To understand the similarities and differences between glue and Onyx
- To know the different sclerosing agents and understand their preparation and delivery technique
- To learn about complications of liquid and sclerosing agents

Friday, June 26

HoW 5

14:15–15:45

Friday, June 26

HoW 6

16:15–17:45

Saturday, June 27

HoW 7

08:00–09:30

Location: Hands-on Workshop Room (Paris)

Pre-registration was necessary. Should you not have pre-registered, please arrive at the workshop room well in advance to check availability.

Wednesday, June 24

08:00-09:45

101 **Plenary Session** **Coils and plugs**

Main Auditorium

*Moderators: A.-M. Belli (London/UK),
M.R. Sapoval (Paris/FR)*

- 101.1 Microcatheters and microwires: basics and distinguishing features
K.A. Hausegger (Klagenfurt/AT)
- 101.2 Importance of coil packing density for peripheral applications
K. Osuga (Suita, Osaka/JP)
- 101.3 Catheter choice for specific embolics
L. Defreyne (Ghent/BE)
- 101.4 The new world of detachable coils
J.-P. Pelage (Caen/FR)
- 101.5 Technical differences between coils: density, fibres and hydrogel
D. Vorwerk (Ingolstadt/DE)
- 101.6 Advanced techniques for coil and plug applications
S.L. Samuels (Miami, FL/US)
- 101.7 Plugs: what's new
G.A. Maleux (Leuven/BE)
- 101.8 Pushable vs. detachable: how to choose
N. McEniff (Dublin/IE)
- 101.9 Recorded clinical cases
S.O. Trerotola (Philadelphia, PA/US)

Moderator summary

10:15-12:00

**201 Parallel Session
HCC**

Main Auditorium

*Moderators: Y. Arai (Tokyo/JP),
M.S. Johnson (Indianapolis, IN/US)*

- 201.1 Chemotherapy and curative options
R. Lencioni (Pisa/IT)
- 201.2 Patient assessment before IR treatment
B. Sangro (Pamplona/ES)
- 201.3 Anatomy for TACE and TARE
R.J. Lewandowski (Chicago, IL/US)
- 201.4 Basics of radioembolisation dosimetry
T.F. Jakobs (Munich/DE)
- 201.5 Radiation segmentectomy and lobectomy
R. Salem (Chicago, IL/US)
- 201.6 Radioembolisation: results and survival data
J.I. Bilbao (Pamplona/ES)
- 201.7 Debate: HCC with portal vein occlusion –
TARE as the treatment of choice
R.J. Lewandowski (Chicago, IL/US)
- 201.8 Debate: HCC with portal vein occlusion –
TACE is an option
Y. Arai (Tokyo/JP)
- 201.9 Debate: drug-eluting embolics are still superior
K. Malagari (Athens/GR)
- 201.10 Debate: classic TACE is still the standard
J. Golzarian (Minneapolis, MN/US)
- 201.11 Downstaging and bridging to transplantation
C.E. Ray, Jr. (Chicago, IL/US)

Moderator summary

10:15-12:00

**202 Parallel Session
GI bleeding**

Lecture Room (Bruselas)

*Moderators: Z.J. Haskal (Charlottesville, VA/US),
O.M. van Delden (Amsterdam/NL)*

- 202.1 Debate: lower GI haemorrhage – interventional radiology first
M. Darcy (St. Louis, MO/US)
- 202.2 Debate: lower GI haemorrhage – endoscopy first
J.J. Vila (Pamplona/ES)
- 202.3 CTA: 1,2,3 or 4 phases
O.M. van Delden (Amsterdam/NL)
- 202.4 Enhancing the negative angiogram:
CO₂ and provocative angiography
J.F. Angle (Charlottesville, VA/US)
- 202.5 Angiography: technique optimisation to identify
the bleeding site
J.E. Jackson (London/UK)
- 202.6 Debate: empiric embolisation for upper
GI haemorrhage – pro
A.-M. Belli (London/UK)
- 202.7 Debate: empiric embolisation for upper
GI haemorrhage – con
S.J. Park (Incheon/KR)
- 202.8 Is there a role for glue or Onyx?
J. Urbano (Madrid/ES)
- 202.9 Lower GI bleeding: how distal do you need to be?
J.E. Jackson (London/UK)
- 202.10 Is there a role for empiric embolisation in the lower
GI tract?
J.F. Angle (Charlottesville, VA/US)
- 202.11 Factors predicting success of embolisation of upper
and lower GI haemorrhage
R. Loffroy (Dijon/FR)

Moderator summary

12:15-13:00

SY 301 Satellite Symposium

For the detailed programme
please refer to page 37.

13:00-13:45

SY 302 Satellite Symposium

For the detailed programme
please refer to page 39.

14:15-15:45

**401 Parallel Session
Endoleak management**

Main Auditorium

*Moderators: R.A. Morgan (London/UK),
H. Rousseau (Toulouse/FR)*

- 401.1 Endoleaks: definitions, frequency and natural history
H. Rousseau (Toulouse/FR)
- 401.2 Embolisation of type I endoleaks
R.A. Morgan (London/UK)
- 401.3 Transarterial embolisation of type II endoleaks: techniques and results
H. Rousseau (Toulouse/FR)
- 401.4 Direct sac embolisation of type II endoleaks: techniques and results
O. Pellerin (Paris/FR)
- 401.5 Cone beam CT guidance for direct sac embolisation of type II endoleaks
O. Pellerin (Paris/FR)
- 401.6 Embolisation for complications after FEVAR, BEVAR and hybrid operations
M.D. Dake (Stanford, CA/US)

- 401.7 Follow-up imaging challenges after sac embolisation

R.A. Morgan (London/UK)

- 401.8 Direct sac and transarterial embolisation of type II endoleaks after TEVAR

H. Rousseau (Toulouse/FR)

Moderator summary

14:15-15:15

**403 Clinical Case-Based Discussions
Prostate artery embolisation**

Lecture Room (Bruselas)

- 403.1 *M.R. Sapoval (Paris/FR)*

- 403.2 *F.C. Carnevale (São Paulo/BR)*

- 403.3 *J.M. Pisco (Lisbon/PT)*

15:15-16:15

**404 Clinical Case-Based Discussions
AVM**

Lecture Room (Bruselas)

- 404.1 *W.F.J. Yakes (Englewood, CO/US)*

- 404.2 *Y.-S. Do (Seoul/KR)*

- 404.3 *P. Rowlands (Liverpool/UK)*

16:15-17:15

**405 Clinical Case-Based Discussions
Radioembolisation made easy**

Lecture Room (Bruselas)

- 405.1 *J.I. Bilbao (Pamplona/ES),*

- 405.2 *G.A. Maleux (Leuven/BE)*

14:15-15:45

**HoW 1 Hands-on Workshop
Coils & Plugs**

Hands-on Workshop Room (Paris)

*Coordinators: K.A. Hausegger (Klagenfurt/AT),
O. van Delden (Amsterdam/NL)*

*Instructors: E. Brountzos (Athens/GR),
M. Darcy (St. Louis, MO/US), J. Urbano (Madrid/ES)*

For more information please refer to page 8.

16:15-17:45

**HoW 2 Hands-on Workshop
Coils & Plugs**

Hands-on Workshop Room (Paris)

*Coordinators: K.A. Hausegger (Klagenfurt/AT),
O. van Delden (Amsterdam/NL)*

*Instructors: A. Basile (Catania/IT), A. Fohlen (Caen/FR),
O. Pellerin (Paris/FR), J. Urbano (Madrid/ES),
P. Vilares Morgado (Porto/PT)*

For more information please refer to page 8.

16:15-17:45

**501 Parallel Session
Portal vein and spleen**

Main Auditorium

*Moderators: M. Darcy (St. Louis, MO/US),
T. Tanaka (Kashihara/JP)*

- 501.1 Splenic artery embolisation in patients with
portal hypertension
S.L. Samuels (Miami, FL/US)

- 501.2 Splenic artery embolisation for hypersplenism
M. Darcy (St. Louis, MO/US)
- 501.3 Partial splenic embolisation (PSE): optimising
embolic materials and outcome
K. Kichikawa (Nara/JP)
- 501.4 BRTO: anatomy and basic principles
S. Hirota (Nishinomiya/JP)
- 501.5 Classic BRTO: sclerosants and coils
K. Osuga (Suita, Osaka/JP)
- 501.6 Classic BRTO: plug-assisted and with gelfoam
D.I. Gwon (Seoul/KR)
- 501.7 BRTO and embolisation for ectopic varices
S. Hirota (Nishinomiya/JP)
- 501.8 Embolisation of portal venous varices during TIPS:
technique and outcome
A. Krajina (Hradec Králové/CZ)
- 501.9 Splenic embolisation to improve liver transplant
function
Z.J. Haskal (Charlottesville, VA/US)

Moderator summary

18:00-18:45

SY 601 Satellite Symposium

For the detailed programme
please refer to page 41.

18:00-18:30

SY 602 Satellite Symposium

For the detailed programme
please refer to page 41.

Thursday, June 25

07:00-07:45

SY 700 Satellite Symposium

For the detailed programme
please refer to page 43.

08:00-09:45

701 Plenary Session Particles and gelfoam

Main Auditorium

*Moderators: T.J. Kroencke (Augsburg/DE),
K. Osuga (Suita, Osaka/JP)*

- 701.1 Microcatheter compatibility for particle delivery
H.T. Abada (Abu Dhabi/AE)
- 701.2 Optimising gelfoam for embolic applications
K. Osuga (Suita, Osaka/JP)
- 701.3 Gelfoam occlusion: permanent or temporary?
M.D. Ferrer-Puchol (Valencia/ES)
- 701.4 Non-resorbable spheres: current practice/
evidence
T.J. Kroencke (Augsburg/DE)
- 701.5 Resorbable spheres: the future?
J. Golzarian (Minneapolis, MN/US)
- 701.6 Correct endpoints using different
embolic particles
P.N.M. Lohle (Tilburg/NL)
- 701.7 Drug-eluting embolics: distinguishing
characteristics
J. Irurzun (Alicante/ES)
- 701.8 In vivo behaviour of drug-eluting embolics:
past concepts & present evidence
J. Namur (Jouy en Josas/FR)
- 701.9 Recorded clinical cases
J.-P. Pelage (Caen/FR)

Moderator summary

THU

10:15-12:00

801 **Parallel Session** **Colorectal metastases**

Lecture Room (Bruselas)

*Moderators: T.F. Jakobs (Munich/DE),
O. Pellerin (Paris/FR)*

- 801.1 Beyond FOLFOX and FOLFIRI: chemotherapy options for the salvage patient
S. Pernot (Paris/FR)
- 801.2 Expanding indications: results of resection and metastasectomy
R. Ciria (Córdoba/ES)
- 801.3 Irinotecan drug-eluting embolics for mCRC: basics, technique and patient management
R. Lencioni (Pisa/IT)
- 801.4 Current evidence and clinical trials for Irinotecan drug-eluting embolics in mCRC
C.E. Ray, Jr. (Chicago, IL/US)
- 801.5 Debate: Skeletonisation prior to radioembolisation – pro
D. Sze (Stanford, CA/US)
- 801.6 Debate: Skeletonisation prior to radioembolisation – con
R. Salem (Chicago, IL/US)
- 801.7 Debate: Skeletonisation prior to radioembolisation – use anti-reflux devices instead
T.F. Jakobs (Munich/DE)
- 801.8 Prevention and management of the complications of radioembolisation including RILD
O. Pellerin (Paris/FR)
- 801.9 Integrating radioembolisation with systemic chemotherapy
S. Pernot (Paris/FR)
- 801.10 Current evidence and clinical trials for radioembolisation in mCRC
M.S. Johnson (Indianapolis, IN/US)
- 801.11 Assessing outcomes: markers, imaging and classification
R.J. Lewandowski (Chicago, IL/US)

Moderator summary

10:15-12:00

802 Parallel Session
Men's health including prostate artery embolisation

Main Auditorium

*Moderators: F.C. Carnevale (São Paulo/BR),
 J.M. Pisco (Lisbon/PT)*

- 802.1 How to start a PAE programme?
M.R. Sapoval (Paris/FR)
- 802.2 Patient selection and pre-procedure work-up including anatomy
H. Rio Tinto (Lisbon/PT)
- 802.3 Standard and new treatments for BPH
N. Thiounn (Paris/FR)
- 802.4 Securing anatomical challenges using cone beam CT
J. Golzarian (Minneapolis, MN/US)
- 802.5 PAE: technical tips
F.C. Carnevale (São Paulo/BR)
- 802.6 Current results and developments
N. Hacking (Southampton/UK)
- 802.7 Embolisation for bladder haemorrhage
R. Loffroy (Dijon/FR)
- 802.8 Embolisation for varicocele: technique and choice of embolic
P. Haage (Wuppertal/DE)

Moderator summary

12:15-13:00

SY 901 Satellite Symposium

For the detailed programme please refer to page 43.

13:00-13:45

SY 902 Satellite Symposium

For the detailed programme please refer to page 45.

14:15-15:45

1001 Parallel Session**Bariatric and other abdominal embolisation**

Main Auditorium

*Moderators: J.-M. Chevallier (Paris/FR),
J. Golzarian (Minneapolis, MN/US)*

- 1001.1 Epidemiology of obesity
J.-M. Chevallier (Paris/FR)
- 1001.2 An update on bariatric surgery
J.-M. Chevallier (Paris/FR)
- 1001.3 Bariatric embolisation, mechanisms, histology
and preclinical data
C.R. Weiss (Baltimore, MD/US)
- 1001.4 Embolisation of gastric artery: a new approach
to the treatment of obesity
C.R. Weiss (Baltimore, MD/US)
- 1001.5 Transarterial therapy for pancreatic cancer
T. Tanaka (Kashiwara/JP)
- 1001.6 Durable means to occlude the bile duct/ureter
E. Brountzos (Athens/GR)
- 1001.7 Embolisation of superior rectal artery for the
treatment of haemorrhoids
V. Vidal (Marseille/FR)
- 1001.8 Embolisation for retroperitoneal haemorrhage
A. Krajina (Hradec Králové/CZ)
- 1001.9 Interventional management of haemobilia
A. Denys (Lausanne/CH)

Moderator summary

14:15-15:15

1003 Clinical Case-Based Discussions
TACE: simple to complex

Lecture Room (Bruselas)

- 1003.1 *S.J. Park (Incheon/KR)*
- 1003.2 *K. Malagari (Athens/GR)*
- 1003.3 *P. Vilares Morgado (Porto/PT)*

15:15-16:15

1004 Clinical Case-Based Discussions
Complex UFE

Lecture Room (Bruselas)

- 1004.1 *N. Hacking (Southampton/UK),*
- 1004.1 *J.B. Spies (Washington, DC/US)*

16:15-17:15

1005 Clinical Case-Based Discussions
Visceral aneurysms: tips and tricks

Lecture Room (Bruselas)

- 1005.1 *V. Vidal (Marseille/FR)*
- 1005.2 *M. Darcy (St. Louis, MO/US)*
- 1005.3 *R.A. Morgan (London/UK)*

HoW 3 14:15-15:45
Hands-on Workshop
Coils & Plugs

Hands-on Workshop Room (Paris)

*Coordinators: K.A. Hausegger (Klagenfurt/AT),
O. van Delden (Amsterdam/NL)*

*Instructors: A. Basile (Catania/IT), A. Fohlen (Caen/FR),
G.A. Maleux (Leuven/BE), J. Urbano (Madrid/ES)*

For more information please refer to page 8.

HoW 4 16:15-17:45
Hands-on Workshop
Particles & Gelfoam

Hands-on Workshop Room (Paris)

*Coordinators: A. Fohlen (Caen/FR),
H. Rio Tinto (Lisbon/PT), D. Vorwerk (Ingolstadt/DE)*

*Instructors: T.J. Kroencke (Augsburg/DE),
K. Malagari (Athens/GR), K. Osuga (Suita, Osaka/JP),
C.R. Weiss (Baltimore, MD/US)*

For more information please refer to page 9.

16:15-17:45

1101 Parallel Session Chest

Main Auditorium

*Moderators: E. Brountzos (Athens/GR),
C.E. Ray, Jr. (Chicago, IL/US)*

- 1101.1 CTA workup for haemoptysis
M.-F. Carette (Paris/FR)
- 1101.2 Technical tips and tricks and embolic agent selection for bronchial artery embolisation
J.E. Jackson (London/UK)
- 1101.3 Bronchial artery embolisation: long-term outcome
G.A. Maleux (Leuven/BE)
- 1101.4 PAVM screening and follow-up after embolisation
S.O. Trerotola (Philadelphia, PA/US)
- 1101.5 Pulmonary AVM: choice of materials and technical tips
S.O. Trerotola (Philadelphia, PA/US)
- 1101.6 Pulmonary artery embolisation for haemoptysis (non AVM)
J.-P. Pelage (Caen/FR)
- 1101.7 Intranodal lymphangiography and thoracic duct embolisation: technical TIPS
R. Salem (Chicago, IL/US)
- 1101.8 Bronchial artery embolisation: how to avoid complications
M.-F. Carette (Paris/FR)

Moderator summary

18:00-18:45

SY 1201 Satellite Symposium

For the detailed programme please refer to page 47.

Friday, June 26

08:00-09:45

1301 Plenary Session Liquid embolics

Main Auditorium

*Moderators: K.A. Hausegger (Klagenfurt/AT),
L. Defreyne (Ghent/BE)*

- 1301.1 Glue: basic principles, mixing and handling
R. Loffroy (Dijon/FR)
- 1301.2 When and how to use glue
M.J. Lee (Dublin/IE)
- 1301.3 Using glue: what I have learned
Y. Arai (Tokyo/JP)
- 1301.4 Sclerosing agent and foam: agent selection
and technical tips
M. Grosso (Cuneo/IT)
- 1301.5 EVOH-based agents (Onyx): basics
R.A. Morgan (London/UK)
- 1301.6 Mastering EVOH-based agents: technical tips
V. Vidal (Marseille/FR)
- 1301.7 Using EVOH-based agents: what I have learned
P. Rowlands (Liverpool/UK)
- 1301.8 Using liquid embolics with balloon occlusion
T. Tanaka (Kashiwara/JP)
- 1301.9 Ethiodised oils (Lipiodol): more than an
embolic transporter
Y. Arai (Tokyo/JP)
- 1301.10 Alcohol: uses, tips and hazards
W.F.J. Yakes (Engelwood, CO/US)
- 1301.11 Recorded clinical cases
Y. Arai (Tokyo/JP)

Moderator summary

10:15-12:00

1401 Parallel Session

Vascular and lymphatic malformations

Main Auditorium

*Moderators: J.A. Reekers (Amsterdam/NL),
W.F.J. Yakes (Englewood, CO/US)*

- 1401.1 The AVM clinic, collaboration and managing patient expectations
A.-M. Belli (London/UK)
- 1401.2 Angioarchitecture of AVMs: a classification system that directs curative therapy
W.F.J. Yakes (Englewood, CO/US)
- 1401.3 Indications for intervention in AVM
J.A. Reekers (Amsterdam/NL)
- 1401.4 Debate: High flow AVMs – alcohol
W.F.J. Yakes (Englewood, CO/US)
- 1401.5 Debate: High flow AVMs – Onyx and glue
P. Rowlands (Liverpool/UK)
- 1401.6 AVMs: alcohol vs. Onyx vs. sclerosant
W.F.J. Yakes (Englewood, CO/US)
- 1401.7 Low-flow AVMs: diagnosis, approach and techniques
J.A. Reekers (Amsterdam/NL)
- 1401.8 Venous outflow occlusion techniques for AVM
P. Rowlands (Liverpool/UK)
- 1401.9 Transcatheter or direct puncture access: which and when?
Y.-S. Do (Seoul/KR)
- 1401.10 The lymphatic malformation: how to treat
J.A. Reekers (Amsterdam/NL)
- 1401.11 Extreme AVM embolisation
Y.-S. Do (Seoul/KR)

Moderator summary

10:15-12:00

**1402 Parallel Session
Trauma**

Lecture Room (Bruselas)

*Moderators: H.T. Abada (Abu Dhabi/AE),
J.F. Angle (Charlottesville, VA/US)*

- 1402.1 Logistics and care pathway: embolisation or surgery first
D. Marrache (Paris/FR)
- 1402.2 Limits of embolisation in splenic trauma: when to refuse
H.T. Abada (Abu Dhabi/AE)
- 1402.3 Splenic trauma: proximal or distal embolisation
A. Denys (Lausanne/CH)
- 1402.4 Hepatic trauma: how and when to embolise
P.K. Ellis (Belfast/UK)
- 1402.5 Blunt and penetrating renal trauma: when and how to embolise
P.K. Ellis (Belfast/UK)
- 1402.6 Pelvic trauma: techniques and results
O.M. van Delden (Amsterdam/NL)
- 1402.7 Lumbar and intercostal artery embolisation
A. Krajina (Hradec Králové/CZ)
- 1402.8 Extremity trauma
S.J. Park (Incheon/KR)
- 1402.9 Embolisation after solid organ and lung biopsy
B.S. Funaki (Chicago, IL/US)
- 1402.10 Embolisation after head and neck trauma
L. Defreyne (Ghent/BE)

Moderator summary

12:15-13:00

SY 1501 Satellite SymposiumFor the detailed programme
please refer to page 49.

13:00-13:45

SY 1502 Satellite Symposium

For the detailed programme
please refer to page 51.

14:15-15:45

**1601 Parallel Session
Cutting edge technology**

Main Auditorium

*Moderators: M.D. Dake (Stanford, CA/US),
P.L. Pereira (Heilbronn/DE)*

- 1601.1 Nanoparticles: are they ready for prime time?
P.L. Pereira (Heilbronn/DE)
- 1601.2 Radiation safety and dose reduction
C.A. Binkert (Winterthur/CH)
- 1601.3 CBCT in liver embolisation: optimising
parameters
D. Sze (Stanford, CA/US)
- 1601.4 Intra-procedural CBCT to assess perfusion and
evaluate embolisation endpoints
O. Pellerin (Paris/FR)
- 1601.5 Advanced 2D and 3D road map techniques to
guide embolisation
P.L. Pereira (Heilbronn/DE)
- 1601.6 Robotic-assisted embolisation
M.R. Sapoval (Paris/FR)
- 1601.7 Accuracy of dual phase CBCT and automatic
tumour-feeding detection software
T. de Baère (Villejuif/FR)
- 1601.8 Fusion imaging: how to use it
J.F. Angle (Charlottesville, VA/US)

Moderator summary

14:15-15:15

**1603 Clinical Case-Based Discussions
TIPS and BRTD**

Lecture Room (Bruselas)

1603.1 *Z.J. Haskal (Charlottesville, VA/US)*1603.2 *E. Brountzos (Athens/GR)*1603.3 *N. McEniff (Dublin/IE)*

15:15-16:15

**1604 Clinical Case-Based Discussions
GI bleeding**

Lecture Room (Bruselas)

1604.1 *H.T. Abada (Abu Dhabi/AE),*1604.2 *N. McEniff (Dublin/IE)*

16:15-17:15

**1605 Clinical Case-Based Discussions
Solid organ/pelvic trauma**

Lecture Room (Bruselas)

1605.1 *J.F. Angle (Charlottesville, VA/US),*1605.2 *O.M. van Delden (Amsterdam/NL)*

14:15-15:45

HoW 5 Hands-on Workshop
Glue, Onyx & liquid embolics, including sclerotherapy

Hands-on Workshop Room (Paris)

*Coordinators: J. Urbano (Madrid/ES),
V. Vidal (Marseille/FR)*

*Instructors: R. Loffroy (Dijon/FR),
S. Samuels (Miami, FL/US),
W.F. Yakes (Englewood, CO/US)*

For more information please refer to page 11.

16:15-17:45

HoW 6 Hands-on Workshop
Glue, Onyx & liquid embolics, including sclerotherapy

Hands-on Workshop Room (Paris)

*Coordinators: J. Urbano (Madrid/ES),
V. Vidal (Marseille/FR)*

*Instructors: R. Loffroy (Dijon/FR),
O. Pellerin (Paris/FR), P. Rowlands (Liverpool/UK)*

For more information please refer to page 11.

16:15-17:45

1701 Parallel Session
Visceral aneurysms

Main Auditorium

*Moderators: M. Grosso (Cuneo/IT),
 M.J. Lee (Dublin/IE)*

- 1701.1 Epidemiology and defining treatment thresholds: does size matter?
K.A. Hausegger (Klagenfurt/AT)
- 1701.2 Strategies and approaches: how to choose
M.J. Lee (Dublin/IE)
- 1701.3 Debate: splenic artery aneurysms – vessel preservation
E. Brountzos (Athens/GR)
- 1701.4 Debate: splenic artery aneurysms – vessel occlusion
Z.J. Haskal (Charlottesville, VA/US)
- 1701.5 Hepatic artery aneurysms: results and complications
P. Waldenberger (Salzburg/AT)
- 1701.6 Renal aneurysms: preserving renal tissue
M.D. Dake (Stanford, CA/US)
- 1701.7 Management of peri-pancreatic aneurysms in patients with celiac trunk occlusion
M. Darcy (St. Louis, MO/US)
- 1701.8 The use of flow diverters for visceral aneurysms
P. Waldenberger (Salzburg/AT)
- 1701.9 Management of isolated internal iliac artery aneurysms
D. Vorwerk (Ingolstadt/DE)

Moderator summary

Saturday, June 27

08:00-09:45

1901 Morbidity and Mortality

Main Auditorium

*Coordinators: C.A. Binkert (Winterthur/CH),
Z.J. Haskal (Charlottesville, VA/US)*

Panelists:

N. Hacking (Southampton/UK)

K.A. Hausegger (Klagenfurt/AT)

A. Krajina (Hradec Králové/CZ)

R.J. Lewandowski (Chicago, IL/US)

D. Sze (Stanford, CA/US)

P. Waldenberger (Salzburg/AT)

08:00-09:30

HoW 7 Hands-on Workshop Glue, Onyx & liquid embolics, including sclerotherapy

Hands-on Workshop Room (Paris)

*Coordinators: J. Urbano (Madrid/ES),
V. Vidal (Marseille/FR)*

*Instructors: H. Abada (Abu Dhabi/AE),
M. Grosso (Cuneo/IT), M.J. Lee (Dublin/IE)*

For more information please refer to page 11.

10:15-12:00
2001 Parallel Session
Oncology – Miscellaneous

Lecture Room (Bruselas)

*Moderators: T. de Baère (Villejuif/FR),
 C.E. Ray, Jr. (Chicago, IL/US)*

- 2001.1 Exotic oncological embolisation
M.S. Johnson (Indianapolis, IN/US)
- 2001.2 Intra-arterial therapy for hepatic metastases of breast cancer
B.S. Funaki (Chicago, IL/US)
- 2001.3 Preop and palliative embolisation of bone tumours
R. García Marcos (Valencia/ES)
- 2001.4 Treatment of metastatic melanoma to the liver: what do we know?
P.L. Pereira (Heilbronn/DE)
- 2001.5 Combined therapy: embolisation and ablation
P. Vilares Morgado (Porto/PT)
- 2001.6 Portal vein embolisation: why and when?
A. Denys (Lausanne/CH)
- 2001.7 Portal vein embolisation: comparison of available materials
T. de Baère (Villejuif/FR)
- 2001.8 Cholangiocarcinoma: current evidence for embolisation
C.E. Ray, Jr. (Chicago, IL/US)
- 2001.9 Current evidence: embolotherapy for neuroendocrine tumours
T. de Baère (Villejuif/FR)
- 2001.10 Renal embolisation: RCC and AML
M.J. Lee (Dublin/IE)

Moderator summary

10:15-12:00

2002 Parallel Session
Women's health

Main Auditorium

*Moderators: J.-P. Pelage (Caen/FR),
J.B. Spies (Washington, DC/US)*

- 2002.1 Minimising radiation dose
C.A. Binkert (Winterthur/CH)
- 2002.2 Agent-specific endpoints in UAE
J.B. Spies (Washington, DC/US)
- 2002.3 Embolisation for adenomyosis
P.N.M. Lohle (Tilburg/NL)
- 2002.4 Ovarian artery embolisation: when, how
and why?
J.B. Spies (Washington, DC/US)
- 2002.5 Treatment of uterine AVM
A.-M. Belli (London/UK)
- 2002.6 Managing early and late complications
T.J. Kroencke (Augsburg/DE)
- 2002.7 Inpatient vs. outpatient UAE
N. Hacking (Southampton/UK)
- 2002.8 UAE vs. surgery: fertility implications
J.A. Reekers (Amsterdam/NL)
- 2002.9 Prophylactic management of the
at-risk pregnancy
A.-M. Belli (London/UK)
- 2002.10 Embolisation for post-partum haemorrhage
T.J. Kroencke (Augsburg/DE)
- 2002.11 Pelvic congestion syndrome: evidence
and results
A. Basile (Catania/IT)

Moderator summary



BECAUSE
EXPERIENCE
MATTERS

INTRODUCING

LifePearl®

Drug-Elutable Beads for embolisation

- New formulation¹
- Enhanced suspension characteristics²
- Tight calibration³
- Syringe presentation

Wednesday, June 24

12:15-13:00

SY 301 Terumo

Interventional oncology, because experience matters

Main Auditorium

Introduction by the moderator

301.1 LifePearl: drug-elutable microspheres.

First in-human experiences

301.2 Occlusafe: potential clinical applications in EU

301.3 HydroPearl: Terumo's new bland embolisation

microspheres. Key features & pre-clinical data

Conclusions & Questions

Concerto™
Detachable Coil System



MVP™
Micro Vascular
Plug System



Onyx™ 34L
Liquid Embolic System



[Don't miss Covidien symposia

**Liquid embolic as an agent for Portal
Vein Embolization and the treatment
of Endoleaks type I and II**

June 24th, Main auditorium, 13:00

**Vascular plugs and detachable coils for
SIRT embolization and the treatment
of acute bleeding**

June 25th, Lecture room Bruselas, 07:00

COVIDIEN, COVIDIEN with logo and Covidien logo
are U.S. and internationally registered trademarks of
Covidien AG. Other brands are trademarks of a Covidien
company. © 2015 Covidien. – EU-15-165420 – 05/2015



COVIDIEN

Wednesday, June 24

13:00-13:45

SY 302 Covidien

Liquid embolic as an agent for portal vein embolisation and treatment of endoleaks type I and II

Main Auditorium

Moderator: I. Keussen (Lund/SE)

Introduction by the moderator

- 302.1 Onyx™ liquid embolic system: a new technique for treatment of type I and II endoleak

D.-D. Do (Berne/CH)

- 302.2 Portal vein embolisation using ethylene-vinyl alcohol copolymer

M. Ronot (Geneva/CH)

Questions and answers

Stay Ahead of the Curve

MagellanTM

Robotic System

Robotic navigation and control during embolization procedures.

Visit the Magellan Symposium:

Wednesday, June 24, 18:00-18:30 in the Bruselas Lecture Room

Indications for Use. The Hansen Medical MagellanTM Robotic System, Hansen MedicalTM Magellan Robotic Catheter and accessory components are intended to be used to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices.

Important Safety Information. As with most invasive procedures, use of the Magellan Robotic System is not without risk. Serious adverse events, some of which can be fatal, may occur, including vascular damage, embolization and stroke. Other potential risks inherent to procedures such as this include loss of limb, catheter entrapment, infection and access site complications (e.g. hematoma), which may require additional surgery. Do not use the system without understanding the instructions for use. For information regarding contraindications, warnings, precautions, adverse events, and methods of use, please see package inserts included with the product. Rx Only Rev 0115

Corporate Headquarters:

800 East Middlefield Road, Mountain View, CA 94043
Telephone: 650 404 5800, Toll Free: 888 404 5801
Fax: 650 404 5901, www.hansenmedical.com



©2015 Hansen Medical, Inc. All rights reserved. Hansen Medical, Heart Design (Logo) and, Hansen Medical (with Heart Design) are registered trademarks of Hansen Medical, Inc. in the United States and other countries. Magellan is a trademark, of Hansen Medical, Inc., in the United States and other countries. AD0010 Rev. A

 **hansen**
MEDICAL
The Global Leader in Intravascular Robotics

Wednesday, June 24

18:00-18:45

- SY 601 Siemens Healthcare**
From established to new embolisation procedures – useful imaging tools
Main Auditorium

- 601.1 Live on stage image processing session: learn how to utilise DynaCT in everyday IO treatment
T.F. Jakobs (Munich/DE)
- 601.2 Bariatric embolisation
C.R. Weiss (Baltimore, MD/US)

18:00-18:30

- SY 602 Hansen Medical**
Clinical update on robotic embolisation
Lecture Room (Bruselas)


Presentations by

- 602.1 *M. Sapoval (Paris/FR)*
- 602.2 *M. Hamady (London/UK)*

DIREXION™ Torqueable Microcatheter

REPOSITION WITHOUT THE WIRE

With best-in-class torque and four tip shape options, the Direxion Microcatheter allows you to re-position the distal tip without a guidewire and facilitate navigation to additional treatment sites.



DIREXION™ DIREXION HI-FLO™

Direxion and HI-FLO are registered or unregistered trademarks of Boston Scientific Corporation or its affiliates. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information for the use only in countries with applicable health authority product registrations. Information not intended for use or distribution in France.

© 2015 Boston Scientific Corporation or its affiliates. All rights reserved. PI-311501-AA APR 2015

Thursday, June 25

07:00-07:45

SY 700 Covidien**Vascular plug and detachable coils for SIRT embolisation and acute bleedings treatment**

Lecture Room (Bruselas)

Moderator: P. Gerwins (Uppsala/SE)

Introduction by the moderator

- 700.1 Clinical experience with MVP™ micro vascular plug system

J. Golzarian (Minneapolis, MN/US)

- 700.2 Embolisation in emergency setting, how to treat?

G. Carrafiello (Varese/IT)

Questions and answers

12:15-13:00

SY 901 Boston Scientific**Master the embolisation – art and science**

Main Auditorium

Moderator: F. Moeslein (Baltimore, MD/US)

- 901.1 Dynamic access solutions with Direxion™ torqueable microcatheter

F. Moeslein (Baltimore, MD/US)


- 901.2 Effective arterial coiling – technical considerations and decision making

F. Wolf (Vienna/AT)

- 901.3 Venous applications? – transferring the art

D. Beckett (London/UK)

The **SIRflox[®]** study



The **data** are building

SIR-Spheres[®]
Y-90 resin microspheres

significantly improved PFS in the **liver¹**

The **SIRFLOX** study

The SIRFLOX study is evaluating the efficacy and safety of adding SIR-Spheres[®] Y-90 resin microspheres to a current first-line chemotherapy in patients with non-resectable colorectal liver metastases. The final results have been submitted to the American Society of Clinical Oncology (ASCO) annual meeting 2015 (29th May–2nd June, Chicago, US).

1. Sirtex ASX announcement, March 17th 2015

www.sirtex.com

SIRTeX

SIR-Spheres[®] is a registered trademark of Sirtex, SIR-Spheres Pty Ltd.

Sirtex Medical Europe GmbH,
Joseph-Schumpeter-Allee 33,
53227 Bonn, Germany
Tel: +49 228 18407 30

Sirtex Medical Limited,
101 Miller Street,
North Sydney, NSW 2060, Australia
Tel: +61 2 9964 8400

Thursday, June 25

13:00-13:45

- SY 902 Sirtex Medical Europe GmbH**
SIRFLOX – a new age of evidence-based interventional radiology
Main Auditorium

Moderator: R. Cianni (Latina/IT)

- 902.1 The SIRFLOX study – latest results and implications
R.A. Sharma (Oxford/UK)

Panel discussion

*B. Garlipp (Magdeburg/DE)**G.A. Maleux (Leuven/BE)**G. Masi (Pisa/IT)**P.L. Pereira (Heilbronn/DE)**P. Rougier (Paris/FR)*



BTG

SYMPOSIUM

WHY EVIDENCE MATTERS

Date: Thursday 25 June
Time: 18:00-18:45
Chair: Dr. José Urbano, Hospital Universitario Fundación Jiménez Díaz Madrid
Venue: Lecture Room Bruselas

Programme

- DC Bead®: Supporting the 4th Pillar of Oncology
- Clinical Outcomes with TheraSphere® in mCRC: Where Are We Now?



DCBead® TheraSphere® BeadBlock®

DC Bead® is CE Marked and is indicated for the treatment of malignant hypervascular tumours and loading with doxorubicin drug. DC Bead® is also indicated for loading with irinotecan for the treatment of metastatic colorectal cancer. Both indications may not be available in your territory. For instructions for use and important safety information, please visit www.dcb bead.com/ifu. In the EU, TheraSphere is CE Marked in the treatment of hepatic neoplasia. For full instructions for use and important safety information, please refer to the TheraSphere package insert or IFU at www.therasphere.com. Bead Block® is CE Marked and indicated for the embolisation of hypervascular tumours, including uterine fibroids*, arteriovenous malformations (AVMs) and the treatment of symptomatic benign prostatic hyperplasia* (BPH). *Size restrictions apply to this indication. For instructions for use and important safety information, please visit www.beadblock.com/ifu. DC Bead and Bead Block are registered trademarks of Biocompatibles UK Ltd, a BTG International group company. TheraSphere is a registered trademark of Theragenics Corporation used under license by Biocompatibles UK Ltd. BTG and the BTG roundel logo are registered trademarks in the US, EU and certain other territories. © 2015 Biocompatibles UK Ltd. All rights reserved.

Thursday, June 25

18:00-18:45

SY 1201 BTG

Why evidence matters

Lecture Room (Bruselas)

Moderator: J. Urbano (Madrid/ES)

1201.1 DC Bead® supporting the 4th pillar of oncology
T. Ferrer (Seville/ES)

1201.2 Clinical outcomes with TheraSphere® in mCRC:
where are we now?
R. Sharma (Oxford/UK)

Join Cook Medical for a special symposium

*Emorrhoid: Embolization of
the Superior Rectal Arteries–
A New Challenge*

Presenter: Dr. Vincent Vidal
Marseille, Fr.

Moderator: Dr. Marc Sapoval
Paris, Fr.

Date: Friday, 26 June

Time: 12:15 - 1:00 pm

Location: Main Auditorium

After the symposium, please join
Dr. Vidal and Dr. Sapoval for a
"Meet the Experts" panel on
hemorrhoid embolization at
the Cook Medical Learning Centre.



www.cookmedical.com

Friday, June 26

12:15-13:00

SY 1501

Cook Medical

Emorrhoid – embolisation of the superior rectal arteries. A new challenge for IR

Main Auditorium

Moderator: M.R. Sapoval (Paris/FR)

1501.1

presentation by

V. Vidal (Marseille/FR)

After the symposium, join Prof. Vidal and Prof. Sapoval for a "Meet the experts" panel on haemorrhoid embolisation at the Cook Medical Learning Centre.

The Complete Embolisation System

Ruby Coil



- Widest range of sizes
2 x 1 cm to 32 x 60 cm
- Enhanced softness profile

POD



- Confident vessel occlusion
- Precise anchoring segment
- Soft packing segment

**On demand detachment.
High-flow microcatheter compatible.**

Penumbra



www.penumbrainc.com

Friday, June 26

13:00-13:45

SY 1502 Penumbra**Penumbra's embolisation and thrombectomy technology: changing the paradigm of peripheral treatment**

Main Auditorium

- 1502.1 Does volume advantage matter? Experience using large volume detachable coils (Ruby™ Coil) in the peripheral vasculature
F. Wolf (Vienna/AT)
- 1502.2 PODTM embolisation device: technology for high flow vessel occlusion
J. Golzarian (Minneapolis, MN/US)
- 1502.3 Revascularisation of acute ischemia and thromboembolic complications in below-the-knee and visceral arterial circulation utilising Indigo® thromboembolectomy system
Z.J. Haskal (Baltimore, MD/US)



BeadBlock®

NOW CE MARK APPROVED FOR PAE*

Meet the Expert: PAE

Dr João Martins Pisco

Hospital St. Louis, Lisbon, Portugal

To recognise CE Mark Approval of Bead Block® for prostate arterial embolisation (PAE)* for the treatment of BPH, BTG is delighted to announce that Dr João Martins Pisco will be sharing his extensive experience of this treatment in our Learning Centre during GEST.

BTG Learning Centre

Please check the BTG booth for further information and timings



*Size restrictions apply to this indication. For instructions for use and important safety information, please visit www.beadblock.com/ifu.

DCBead® TheraSphere® BeadBlock®

DC Bead® is CE Marked and is indicated for the treatment of malignant hypervascular tumours and loading with doxorubicin drug. DC Bead® is also indicated for loading with irinotecan for the treatment of metastatic colorectal cancer. Both indications may not be available in your territory. For instructions for use and important safety information, please visit www.dcbear.com/ifu. In the EU, TheraSphere is CE Marked in the treatment of hepatic neoplasia. For full instructions for use and important safety information, please refer to the TheraSphere package insert or IFU at www.therasphere.com. Bead Block® is CE Marked and indicated for the embolisation of hypervascular tumours, including uterine fibroids*, arteriovenous malformations (AVMs) and the treatment of symptomatic benign prostatic hyperplasia* (BPH). *Size restrictions apply to this indication. For instructions for use and important safety information, please visit www.beadblock.com/ifu. DC Bead and Bead Block are registered trademarks of Biocompatibles UK Ltd, a BTG International group company. TheraSphere is a registered trademark of Theragenics Corporation used under license by Biocompatibles UK Ltd. BTG and the BTG roundel logo are registered trademarks in the US, EU and certain other territories. © 2015 Biocompatibles UK Ltd. All rights reserved.

Learning Centres

The Learning Centres at GEST Europe 2015 will provide an excellent opportunity for all congress delegates to test the latest interventional devices, gain hands-on experience with new equipment and talk to industry representatives.

Please note that the CIRSE Foundation is not responsible for the information provided at the Learning Centres.

BTG

We are running a comprehensive programme in the BTG Learning Centre:

Meet the expert: How to perform PAE

J.M. Pisco (Lisbon/PT)

Thursday, June 25	14:00-15:00
Friday, June 26	11:30-12:30 and 16:00-17:30

Workshop: Medical writing and publishing

Friday, June 26	10:00-11:00 and 14:00-15:00
-----------------	-----------------------------

Meet the expert: Driving consistency with DC Bead® and hands-on embolisation workshop

Wednesday, June 24	10:00-10:30 and 14:00-14:30
Thursday, June 25	10:00-10:30
Friday, June 26	13:00-13:30

Meet the expert: TheraSphere®: Optimising ⁹⁰Y microspheres for the treatment of liver cancer


Wednesday, June 24	15:00-15:30
Thursday, June 25	09:00-09:30 and 16:00-16:30
Friday, June 26	09:00-09:30 and 17:15-17:45

Please visit the BTG booth for more information

LIPIODOL® ULTRA FLUID

the value of iodinated fatty acids of poppy seed oil

Efficacy & safety of Lipiodol® for improved overall survival in HCC



LIPIODOL® ULTRA-FLUID. Composition: Ethyl esters of iodinated fatty acids of poppy seed oil 10 mL, corresponding to an iodine content of 480 mg/mL. **Indications:** (1) In diagnostic radiology: - Hysterosalpingography - Ascending uerthrography - lymphography - Sialography - Fistulography and exploration of abscesses - Exploration of biliary sinuses - Pre and postoperative cholangiography. In interventional radiology: - Chemoembolization of hepatocarcinoma (HCC), where the agent can be used in two different ways: a- Chemotherapy where Lipiodol Ultra-Fluid is administered in combination with a cytotoxic drug. b- Chemoembolization where the preceding technique is associated with embolization of the artery (using gelatin or sponge) for example. - Selective embolization in combination with Histoacryl glue (particularly for arteriovenous malformations or aneurysms). - Selective injections of Lipiodol Ultra-Fluid into the hepatic artery for diagnostic purposes where a spiral CT scan is not practical. In endocrinology: - Prevention of severe cases of iodine deficiency. **Possology and method of administration:** (2) It has to be adapted according to the type of examination, the territories explored, the age and weight of the patient. The volume to be administered depends on the particular requirements of the technique and the size of the patient. **Contraindications:** Hypersensitivity to Lipiodol Ultra-Fluid - Manifest hyperthyroidism - Patients with traumatic injuries, recent haemorrhage or bleeding - Hysterosalpingography during pregnancy or acute pelvic inflammation - Bronchography. In interventional radiology (Chemoembolization), the toxicity of intra-arterial chemotherapy using Lipiodol Ultra-Fluid which loads the bile duct means the treatment is contraindicated in areas of the liver where the bile ducts are dilated, unless there is post drainage. **Special warnings and special precautions for use:** (3) Lymphography: pulmonary embolization occurs in a majority of patients following lymphography with Lipiodol Ultra-Fluid. Radiological or radioisotopic monitoring during the injection is recommended to minimize this pulmonary embolization. Hypersensitivity: all iodinated contrast agents can lead to minor or major hypersensitivity reactions, which can be life-threatening. These hypersensitivity reactions are of an allergic nature (known as anaphylactic reactions if they are serious) or a non-allergic nature. They can be immediate (occurring within 60 min) or delayed (not occurring until up to 7 days later). Anaphylactic reactions are immediate and can be fatal. They are dose-independent, can occur right from the first administration of the product, and are often unforeseeable. Thyroid: can cause hyperthyroidism in predisposed patients. Lymphography saturates the thyroid with iodine for several months and thyroid exploration should be performed before radiological examination. Chemoembolization: renal insufficiency must be prevented by correct rehydration before and after the procedure. Occluded vessels must be carefully monitored. Hepatic intra-arterial treatment can progressively cause an irreversible liver insufficiency in patients with serious liver malfunction. Embolization with glue: the compatibility between each batch of Lipiodol Ultra-Fluid and glue must be checked in vitro before use. **Interaction with other medicinal products and other forms of interaction:** (4) Metformin, beta blockers, vasoactive substances, angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, Diuretics, Interleukin II. **Fertility, pregnancy and lactation:** (5) - Effects on ability to drive and use machines: (6) - Undesirable effects: (7) most adverse effects are dose-related and dosage should therefore be kept as low as possible: hypersensitivity, anaphylactic reaction, anaphylactoid reaction, vomiting, diarrhea, nausea, fever, pain, dyspnea, cough, hypothyroidism, hyperthyroidism, thyroiditis, pulmonary embolism, cerebral embolism, retinal arterial embolism, lymphoedema aggravation, hepatic vein thrombosis, granuloma. **Overdose:** (8) - Pharmacodynamic properties: (9) Pharmacotherapeutic group: X-ray contrast media, iodinated. **Presentation:** (10) - 5 mL glass ampoule, box of 4 - 10 mL glass ampoule, box of 1 - 5 mL glass ampoule, box of 100 - 10 mL glass ampoule, box of 50. **Marketing authorisation holder:** (11) Guerbet - BP 57400 - F-95943 Roissy-CDG cedex - FRANCE. **Information:** M: 33 (0) 1 45 91 50 00. **Revision:** October 19th, 2011

(*) for complete information please refer to country's local SPC. (**) Indications may differ between countries. (***) All precautions may not be marketed

Learning Centres

Cook Medical

Improve your embolisation kit with the most recent coil technology

H. Rio Tinto (Lisbon/PT)

Wednesday, 24 June

13:45-14:15

Learn basic and advanced IR techniques with Cook's Vista educational program

H. Rio Tinto (Lisbon/PT)

Thursday, 25 June

13:45-14:15

Controversies in pelvic vein embolisation

T. Lopez (London/UK)

Friday, 26 June

09:45-10:15

The Cook Medical Learning Centre will remain open and available for physicians who would like to learn more about our embolic therapies products. Hands-on models will be available for product demonstrations.

THINK EMBOLICS. DISCOVER MERIT.™



HEPASPHERE™ | EMBOSPHERE® | EMOGOLD®
BEARING nsPVA® | MERIT MAESTRO®

Our embolotherapy heritage started
nearly 20 years ago and continues to focus
on understanding the needs of our physician
partners to innovate clinically sound solutions
and deliver optimal outcomes.

Our future is together.

BOOTH 3

MeritEMEA.com +31 43 358 82 22



PERIPHERAL INTERVENTION

Sponsors Hands-on Workshops

The hands-on workshops are kindly supported by:

- **B.Braun Surgical, S.A.**
- **Baxter**
- **Boston Scientific**
- **BTG**
- **Celonova Biosciences**
- **Chemische Fabrik Kreussler & Co. GmbH**
- **Cook Medical**
- **Covidien**
- **GEM Srl**
- **Merit Medical**
- **Penumbra**
- **PharmaCept**
- **Terumo Europe**
- **Vascular Solutions**

For detailed information on the hands-on workshops, please refer to pages 8–11.

For further information about the industry partners, please refer to the Technical Exhibitors Guide.

If you are interested in obtaining product information outside of the hands-on workshop sessions, please visit the respective company booth in the exhibition area.

Technical Exhibition (Alphabetical List)

Company	Booth No.
ALN	16
AngioDynamics	8a
Balt	7
Boston Scientific	11
BTG	6
CeloNova BioSciences	1
CIRSE 30 Years	20
Cook Medical	10
Covidien	13
EndoShape	15a
Endovascular Today	19
GEM	17
Guerbet	9
Hansen Medical	5
Interventional News / BIBA	18
Merit Medical	3
Penumbra	12
PharmaCept	14
Sirtex Medical	4
Surefire	15
Terumo	8
Vascular Solutions	2

Technical Exhibition (Numerical List)

Company	Booth No.
CeloNova BioSciences	1
Vascular Solutions	2
Merit Medical	3
Sirtex Medical	4
Hansen Medical	5
BTG	6
Balt	7
Terumo	8
AngioDynamics	8a
Guerbet	9
Cook Medical	10
Boston Scientific	11
Penumbra	12
Covidien	13
PharmaCept	14
Surefire	15
EndoShape	15a
ALN	16
GEM	17
Interventional News / BIBA	18
Endovascular Today	19
CIRSE 30 Years	20

Technical Exhibitors Guide

ALN Implants Chirurgicaux

16

589, Chemin du Niel
83230 Bormes les Mimosas, France
Tel.: +33 4 94 01 05 01
Fax: +33 4 94 01 09 01
E-mail: contact@aln2b.com
www.aln2b.com

Company: ALN is one of the leaders in its field with its ALN optional vena cava filter. This filter is well known in Europe for more than 20 years and is present for long on international markets including USA.

Products: New ALN Optional vena cava filter with Hook
ALN Optional vena cava filter
Retrieval systems of the ALN filter
CE Mark & FDA approved (2008), Proven effectiveness,
Retrieval after long placements (over 40 months);

AngioDynamics

8a

Haaksbergweg 75 (Margriet Toren)
1101 BR Amsterdam Z-O, The Netherlands
Tel.: +31 20 753 2949
Fax: +31 20 753 2939
E-mail: amsterdam@angiodynamics.com
www.AngioDynamics.com

AngioDynamics is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology.

Within oncology, our diverse product lines include NanoKnife System – the first in class device for Irreversible Electroporation (IRE) to irreversibly electroporate cell membranes. For thermal ablation, we offer both Microwave technology with the Acculis System and Temperature controlled Radio-frequency ablation with the StarBurst system.

Visit AngioDynamics booth and find out more on how our range of products benefits patients, physicians and health care providers in the areas of Irreversible electroporation and thermal ablation.

Balt**7**

10 rue Croix Vigneron
95160 Montmorency, France
www.balt.fr

Founded in 1977, Balt is a pioneering family company, always leading in Interventional Neuroradiology, and for nearly 40 years, Balt has been supporting the development of endovascular therapies. Balt completely controls its R&D policy with the constant underlying objective of innovating, making it one of the world leaders in its field. Constantly growing, Balt remains the one and only European company facing multinationals.

Balt is one of the leaders in arteriovenous malformations treatment devices and in new generations of vascular stents 'Flow-diverter' to treat aneurysms. Balt also designs, manufactures and commercializes intracranial microcatheters, stents and access systems.

Inventor of the flow-dependant microcatheter (MAGIC, 1987), as well as the intracranial braided stent (LEO, 2003), the stent-retriever (CATCH, 2005) and the Flow-diverter (SILK, 2006), Balt always had a significant influence on the Interventional Neuroradiology's progress.

Boston Scientific**11**

www.bostonscientific.eu

Boston Scientific (NYSE: BSX) is a worldwide developer, manufacturer and marketer of medical devices with approximately 23,000 employees and revenue of \$7.380 billion in 2014. Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.eu and connect on Twitter (@bostonsci) and Facebook.

BTG International Ltd**6**

5 Fleet Place
EC4M 7RD London, United Kingdom
Tel.: +44 20 7575 0000
www.btgplc.com

At BTG we are focused on bringing to market innovative products in specialist areas of medicine to better serve doctors and patients. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of liver tumours, severe blood clots, varicose veins and advanced emphysema, while our Specialty Pharmaceuticals portfolio offers antidotes that alleviate toxicity and treat rare conditions. Inspired by a deep understanding of our customers' needs, we're working to meaningfully improve the lives of patients and their healthcare experience. Many of our products combine medicines, device technology and new techniques in order to deliver more targeted treatments. We also invest in the clinical evidence that helps demonstrate the value of our products to doctors, patients, and healthcare systems. Doing what's right for patients is what gets us to work in the morning. It's part of our DNA. By staying true to this principle and our values, we've earned a strong reputation for the quality of our products and our commitment to innovation. Whether developed in our own labs or in partnership with clinicians, academics, and other companies, we believe passionately that medical innovation has the power to improve human health.

CeloNova BioSciences, Inc.**1**

18615 Tuscany Stone Ste 100
TX 78258 San Antonio, United States
Tel.: +1 888 388 3888
Fax: +1 210 403 2008
E-mail: info@celonova.com
www.celonova.com

CeloNova BioSciences, Inc., headquartered in San Antonio, Texas, is a global medical device company that develops, manufactures, and markets innovative Interventional Cardiology and Radiology products.

Embozene™ Microspheres are spherical embolics, available in 40 µm up to 1300 µm and are tightly calibrated for targeted embolization. TANDEM™ Microspheres small sizes and precise calibration allow superselective embolization designed for distal penetration that may increase tumor response. For additional information, visit www.celonova.com.

CIRSE – Cardiovascular and Interventional Radiological Society of Europe **20**

Neutorgasse 9
1010 Vienna, Austria
Tel.: +43 1 904 2003
Fax: +43 1 904 2003 30
E-mail: info@cirse.org
www.cirse.org

CIRSE is a non-profit scientific and educational society with over 6,500 members and 36 national group members. The society supports the development of all areas of image-guided medicine, through educational meetings, scientific publications, public awareness campaigns and collaboration with other medical or scientific organisations. CIRSE places a strong emphasis on embolisation, aiming to strengthen the increasingly vital role of embolotherapy in patient care. The CIRSE Foundation, an independent, non-profit and tax-exempt foundation that complements CIRSE's activities, both supports GEST Europe's biennial meetings and sponsors courses on the topic, which are organised by CIRSE's European School of Interventional Radiology (ESIR). In addition, CIRSE hosts ESIRonline, the largest online educational platform for interventional radiological procedures. Presentations and slides from GEST Europe 2015 will be available online soon. For more information, visit www.cirse.org, www.esir.org, or www.gest2015.eu.

Cook Medical**10**

O'Halloran Road,
National Technology Park,
Limerick, Ireland
Tel.: +353 61 334440
Fax: +353 61 334441
www.cookmedical.com

A global pioneer in medical breakthroughs, Cook Medical is committed to creating effective solutions that benefit millions of patients worldwide. Today, we combine medical devices, drugs, biologic grafts and cell therapies across more than 16,000 products serving more than 40 medical specialties. Founded in 1963 by a visionary who put patient needs and ethical business practices first, Cook is a family-owned company that has created more than 10,000 jobs worldwide. For more information, visit www.cookmedical.com.

Covidien AG**13**

Victor Von Bruns-Strasse 19
8212 Neuhausen Am Rheinfall, Switzerland
Tel.: +41 44 308 48 48
www.covidien.com

Both Covidien and Medtronic are committed to improving the lives of people through our medical technologies. We brought our two companies together to accelerate and advance our ability to create meaningful innovations for hospitals, health systems, and health care providers so they can deliver the best care possible to patients and their families around the world.

We recognize that innovation is only meaningful if it is safe, effective, and usable. That's why we are partnering with health systems and providers to combine our capabilities with their expertise to change the way we work together to achieve the best outcomes.

With changing healthcare demands, companies that deliver health products and services must be willing to do things differently. The union of Medtronic and Covidien demonstrates that we are committed to thinking differently in solving problems to deliver better health. As we go forward, we will

keep you updated about how this approach is succeeding in ensuring better health for more people.

To learn more about our products and therapies, please visit us at Booth #13.

EndoShape, Inc.

15a

5425 Airport Boulevard, Suite 101

CO 80301 Boulder, United States

E-mail: customerservice@endoshape.com

www.endoshape.com

EndoShape, Inc. is making a real difference in patients' lives and physicians' practices by providing superior embolization products. EndoShape is creating a strong Peripheral Vascular (PV) embolization business based on our proprietary radio-paque polymer and our novel product designs. We have obtained 510(k) clearance and launched the Medusa® Multi-Coil (MMC) in the United States. Our customers have performed over 140 clinical cases in the US. Patients have been treated for pelvic congestion syndrome and varicoceles, trauma-related internal bleeding and therapeutic embolization of internal iliac arteries as part of endovascular repair of aortic aneurysms. EndoShape is developing a full catalog of novel PV products, including embolic beads, and a neuro-vascular product line.

Endovascular Today Europe

19

1008 Upper Gulph Road, Suite 200

PA 19087 Wayne, United States

E-mail: cphillip@bmctoday.com

www.evtoday.com

Endovascular Today Europe is the premier publication for all specialists engaged in endovascular therapies. Published 7 times a year with a twice monthly online e-news, each issue of Endovascular Today Europe features timely articles on new techniques, clinical trial results, case studies, and advances in technology for endovascular practitioners. Endovascular Today Europe is distributed to 10,000 endovascular specialists in Europe.

GEM Srl**17**

Via dei Campi 2, PO Box 427
55049 Viareggio, Italy
Tel.: +39 0584 389784/391388
Fax: +39 0584 397904
E-mail: info@gemitaly.it
www.gemitaly.it

GEM srl, Italian firm established in 1994 produces (under GLUBRAN brand) and distributes all over the world synthetic glues: GLUBRAN 2 for Surgical and Endovascular use and GLUBRAN TISS for skin application.

GEM srl also produces and distributes application devices suitable for the use of these glues: Dispensing Tips, Catheters for Laparoscopy, Drop Control Devices, Spray Devices; 1ml Luer lock syringes and vascular closure devices specific for femoral accesses. All GLUBRAN products are CE marked.

Guerbet**9**

BP 57400
95943 Roissy CdG Cedex, France
Tel.: +33 1 4591 5000
www.guerbet.com

Guerbet is a pioneer in the contrast agent field, with more than 90 years' experience, and is the only pharmaceutical group dedicated to medical imaging worldwide. It offers a comprehensive range of X-Ray, Magnetic Resonance Imaging (MRI) and Interventional Radiology and Theranostics (IRT) products, along with a range of injectors and related medical devices to improve the diagnosis and treatment of patients. To discover new products and ensure future growth, Guerbet devotes significant resources to R&D, spending around 9% of its sales each year. Guerbet (GBT) is listed on NYSE Euronext Paris (Segment B – Mid Caps) and generated revenue of €409 million in 2014. It had a total workforce of 1,461 employees at 31 December 2014.

Hansen Medical**5**

800 E. Middlefield Rd.

CA 94043 Mountain View, United States

Tel.: +1 650 404 5800

E-mail: info@hansenmedical.comwww.hansenmedical.com

Hansen Medical®'s Magellan™ Robotic System is intended to be used to facilitate navigation in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices. The Magellan Robotic System is designed to deliver predictability, control and catheter stability to endovascular procedures. Since its commercial introduction in the U.S. and Europe, the Magellan Robotic System has demonstrated its clinical versatility in many cases in a broad variety of peripheral vascular procedures globally. The Magellan Robotic System offers several important features including:

- Provides predictability, control and catheter stability as a physician navigates a patient's peripheral vasculature and then provides a conduit for manual treatment of vascular disease with standard therapeutic devices.
- Is designed to enable more predictable procedure times and increased case throughput potentially allowing hospitals to improve utilization within their vascular business line.
- Employs an open architecture designed to allow for the subsequent use of many therapeutic devices on the market today.
- Is designed to potentially reduce physician radiation exposure and fatigue by allowing the physician to navigate procedures while seated comfortably at a remote workstation away from the radiation field and without wearing heavy lead as required in conventional endovascular procedures.
- The Magellan 6Fr Robotic Catheter allows for independent robotic control of two separate bend sites on a single catheter, as well as robotic manipulation of standard guide wires.

Interventional News**18**

526 Fulham Road
SW6 5NR London, United Kingdom
Tel.: +44 20 7736 8788
Fax: +44 20 7736 8283
E-mail: shilpa@bibamedical.com
www.interventional.com

Interventional News is a specialised, quarterly newspaper which goes out to over 12,100 subscribers in Europe and North America. Published by BIBA Medical, it is an editorially independent news brand, steered by internationally renowned editors-in-chief, Professor Andy Adam and Dr. Brain Stainken. Interventional News contains the latest news, opinion from thought leaders in interventional radiology, summaries of cutting-edge research, expert analysis, conference coverage, information and updates on the latest products and the medical device industry. Please visit www.interventionalnews.com for regular breaking news updates and download the IN app for Apple devices from the app store for live conference coverage. Stay in touch with the latest developments in the world of intervention – get your free subscription to the print copy of Interventional News and our fortnightly e-newsletters at www.cxvascular.com.

Merit Medical EMEA**3**

Amerikalaan 42

6199 AE Maastricht-Airport, The Netherlands

Tel.: +31 43 358 82 22

Fax: +31 43 358 82 21

E-mail: marketingemea@merit.comwww.meritEMEA.com

Our embolotherapy heritage started nearly 20 years ago and continues to focus on understanding the needs of our physician partners to innovate clinically sound solutions and deliver optimal outcomes. We look forward to the opportunity at GEST Europe 2015 to showcase our extensive embolotherapy portfolio, including our HepaSphere™ Microspheres and Embosphere® Microspheres, the most clinically studied and clinically proven round embolic. In addition to microspheres and embolisation particles, we offer high-performance delivery systems such as our Merit Maestro® Microcatheter and our Tenor® Micro Guide Wire. Visit us at booth 3 to learn more about our innovative products, clinical support, and educational and training opportunities – all backed by a dedicated sales and customer service staff.

Merit Medical Systems, Inc. has been a global leader in the development, manufacturing, and distribution of proprietary disposable and implantable medical devices for interventional and diagnostic radiology, cardiology, embolotherapy, and vascular surgery for nearly 30 years. Merit Medical has built a solid reputation for introducing and marketing innovative, high-quality products designed to enhance the practice of interventional medicine.

Penumbra Europe GmbH**12**

Am Borsigturm 44
13507 Berlin, Germany
Tel.: +49 30 200 56 76 0
E-mail: info@penumbrainc.de
www.penumbrainc.com

Penumbra is a specialty interventional therapies company that develops and markets innovative medical devices to treat challenging medical conditions with significant unmet clinical needs. We design our therapies to provide our specialist physician customers with improved clinical outcomes through faster and safer procedures at significant overall cost savings to the healthcare system. Today we have over 800 employees with sales operations in North America, Europe, Australia and Asia.

PharmaCept**14**

Bessemmerstraße 82
12103 Berlin, Germany
Tel.: +49 756 5985 0
Fax: +49 756 5985 11
E-mail: info@pharmacept.com
www.pharmacept.com

PharmaCept stands for a successful development of niche products and instructions in the area of cancer treatment with a special focus on research in Interventional Oncology. The main pillar of our company's development is in the field of chemoembolization therapy. On the basis of the Barcelona guidelines for the treatment of primary liver cell carcinoma, chemoembolization has become an integral part of the treatment of this illness. Increasing experience has shown that the use of permanent vascular occlusion materials promotes the development of new blood vessels which sustain tumor growth. As well as stimulating growth, permanent vascular occlusion also exacerbates pain. With EmboCept® S, our biodegradable starch microspheres, these side effects can be considerably reduced.

New clinical studies will now further scientifically explore the already known advantages of short-term vessel-blockage and unlimited combination with drugs, e.g. our Cisplatin powder named PlatiCept® with the use of our embolizate EmboCept® S.

Sirtex Medical Europe GmbH

4

Joseph-Schumpeter-Allee 33

53227 Bonn, Germany

Tel.: +49 228 18407 30

Fax: +49 228 18407 35

E-mail: info@sirtex-europe.com

www.sirtex.com

Sirtex Medical is actively engaged in the field of liver-directed therapies for cancer patients.

The innovative technology of Sirtex, SIR-Spheres® Y-90 resin microspheres (microscopic Yttrium-90 resin beads), is a medical device used in interventional oncology to deliver Selective Internal Radiation Therapy (SIRT) to the liver. SIR-Spheres® Y-90 resin microspheres were approved in 2002 for use in the treatment of unresectable liver tumours within the European Union under a CE Mark and for the treatment of colorectal cancer liver metastases in combination with FUDR intra-arterial chemotherapy by the US Food & Drug Administration. SIR-Spheres® Y-90 resin microspheres are presently used to treat a variety of unresectable liver metastases as well as in hepatocellular carcinoma at 250+ institutions in Europe and the Middle East, 380+ centres in North America and 100+ in Asia-Pacific region. To date, more than 50,000 treatments have been delivered world-wide. The SIRFLOX study - the largest randomised interventional radiology study ever conducted in oncology - evaluating SIR-Spheres® Y-90 resin microspheres in combination with a current chemotherapy regimen for the first-line treatment of unresectable colorectal liver metastases (mCRC) shows an additional 7.9 months (12.6 vs 20.5 months) improvement in median PFS in the liver for patients whose treatment includes SIR-Spheres® Y-90 resin microspheres.

Surefire Medical, Inc.**15**

6272 W. 91st Avenue
CO 80031 Westminster, United States
Tel.: +1 303 426 1222
E-mail: info@surefiremedical.com
www.surefiremedical.com

Surefire Medical, Inc., based in Westminster, Colorado, USA, was founded in 2009 to develop innovative infusion systems for the interventional radiology and interventional oncology markets. Surefire's infusion systems are designed to precisely deliver embolic agents through a unique microcatheter with an expandable tip, which collapses in forward flow and dynamically expands to the vessel wall in reverse flow. Recent clinical studies suggest that the resulting pressure gradient changes preferentially shunt particles into the tumor compartment, temporarily increasing uptake by the tumor but not normal liver tissue. For clinical trial results, and more information please visit www.surefiremedical.com.

Terumo Europe**8**

Interleuvenlaan 40
3001 Leuven, Belgium
Tel.: +33 1 47 1609 30
Fax: +33 1 47 1609 49
www.terumo-europe.com

Rising to the challenge of innovation

Founded in Tokyo in 1921, Terumo is a multinational company with more than 90 years' experience in developing best in class medical devices. With our corporate mission of "Contributing to Society through Healthcare," we work proactively to provide high-quality medical devices and services for the benefit of patients and medical practitioner in over 160 countries.

Rising to the challenge of innovating for patients, Terumo brings you a complete range of Interventional Embolization and Oncology products:

- Leading edge access and delivery systems (Radiofocus® Guidewire GT, Progreat®, Glidecath®)
- Complete range of embolic devices (AZUR® Peripheral HydroCoil®)
- Ablation systems (MicroThermX®)
- Microspheres (drug-elutable and bland)

Having pioneered the field of Interventional Embolization and Oncology, Terumo is committed to bringing you cutting edge technology that is safer, more effective and easier to use. We are also committed to support our comprehensive product portfolio by a well-trained field force and solid clinical evidence.


Vascular Solutions


2

6464 Sycamore Court N
MN 55369 Minneapolis, United States
Tel.: +1 763 565 4300
www.vascularsolutions.com

Driven by clinical needs and supported by innovative thinking, Vascular Solutions offers a rapidly growing product line that spans both established and emerging areas of coronary and peripheral vascular treatments. Cardiologists, radiologists, electrophysiologists and vein specialists worldwide rely on the quality and proven clinical effectiveness of our products.

Vascular Solutions will be featuring several embolization products including Gel-Bead™ embolization spheres. These bioresorbable, gelatin spheres are precisely sized for targeted occlusion of hypervascular tumors and provide even, predictable distribution. Gel-Block™ 10x embolization pledgets will also be showcased. Gel-Block 10x consists of ten pre-formed, ready-to-use gelatin foam pledgets that are uniform in size for precise delivery and consistent expansion. Additionally, Vascular Solutions will feature the Elite™ snares designed for rapid deployment and secure capture. Please see the Instructions for Use for a complete listing of the indications, contraindications, warnings and precautions.





Imprint

CIRSE Central Office

Neutorgasse 9
1010 Vienna, Austria

Phone: +43 1 904 2003

Fax: +43 1 904 2003 30

E-mail: office@esir.org

Web: www.gest2015.eu

The GEST Europe 2015 Pocket Guide

In case of any enquiries or comments,
please contact us at **office@esir.org**

© CIRSE Foundation / 2015

GraphX by L O O P . E N T E R P R I S E S media
www.loop-enterprises.com



SEE MORE.
REACH FURTHER.
TREAT SMARTER.



You are invited to a Workshop on Medical Writing and Publishing

Date: Friday 26 June **Time:** 10am and 2pm
Venue: BTG Learning Centre

This workshop will provide practical guidance and templates on how to:

- Understand the fundamentals for good medical writing
- Structure and write a scientific paper
- Choose the right journal to submit to
- Maximise your acceptance chances

Spaces are limited so please reserve your place by emailing helen.barnard@btgplc.com



Imagine where we can go.



'Imagine where we can go', 'See More. Reach Further. Treat Smarter', BTG and the BTG roundel logo are trademarks of BTG International Ltd. BTG and the BTG roundel logo are registered trademarks in the US, EU and certain other territories. © 2015 Biocompatibles UK Ltd. All rights reserved.

btg-lm.com